Extracellular Matrix and αβ Integrin Signaling Control the Maintenance of Bone Formation Capacity by Human Adipose-derived Stromal Cells
Authors
Affiliations
Stromal vascular fraction (SVF) cells of human adipose tissue have the capacity to generate osteogenic grafts with intrinsic vasculogenic properties. However, adipose-derived stromal/stem cells (ASC), even after minimal monolayer expansion, display poor osteogenic capacity in vivo. We investigated whether ASC bone-forming capacity may be maintained by culture within a self-produced extracellular matrix (ECM) that recapitulates the native environment. SVF cells expanded without passaging up to 28 days (Unpass-ASC) deposited a fibronectin-rich extracellular matrix and displayed greater clonogenicity and differentiation potential in vitro compared to ASC expanded only for 6 days (P0-ASC) or for 28 days with regular passaging (Pass-ASC). When implanted subcutaneously, Unpass-ASC produced bone tissue similarly to SVF cells, in contrast to P0- and Pass-ASC, which mainly formed fibrous tissue. Interestingly, clonogenic progenitors from native SVF and Unpass-ASC expressed low levels of the fibronectin receptor α integrin (CD49e), which was instead upregulated in P0- and Pass-ASC. Mechanistically, induced activation of αβ integrin in Unpass-ASC led to a significant loss of bone formation in vivo. This study shows that ECM and regulation of αβ-integrin signaling preserve ASC progenitor properties, including bone tissue-forming capacity, during in vitro expansion.
Targeting integrin pathways: mechanisms and advances in therapy.
Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z Signal Transduct Target Ther. 2023; 8(1):1.
PMID: 36588107 PMC: 9805914. DOI: 10.1038/s41392-022-01259-6.
Huang R, Fu R, Yan Y, Liu C, Yang J, Xie Y Bioeng Transl Med. 2022; 7(3):e10312.
PMID: 36176620 PMC: 9472001. DOI: 10.1002/btm2.10312.
Miyazaki S, Funamoto T, Sekimoto T, Kurogi S, Ohta T, Nagai T Acta Histochem Cytochem. 2022; 55(3):99-110.
PMID: 35821749 PMC: 9253499. DOI: 10.1267/ahc.22-00027.
Manferdini C, Trucco D, Saleh Y, Gabusi E, Dolzani P, Lenzi E Gels. 2022; 8(6).
PMID: 35735726 PMC: 9222613. DOI: 10.3390/gels8060382.
Cheng C, Chaaban M, Born G, Martin I, Li Q, Schaefer D Front Bioeng Biotechnol. 2022; 10:841690.
PMID: 35350180 PMC: 8957819. DOI: 10.3389/fbioe.2022.841690.